GlycoEra AG

GlycoEra AG is a Swiss biotechnology company founded in 2020, focused on developing biologics that enable the selective degradation of disease-driving extracellular proteins. Their proprietary platform leverages glycoengineering and protein design to create highly specific degraders that can rapidly and effectively target pathogenic proteins, including autoantibodies, with minimal off-target effects. The company aims to revolutionize autoimmune disease treatment by providing more precise and early intervention options.